Our medical, nursing and allied health clinicians are increasingly involved in research to improve the care of our patients. This is reflected in the breadth of our research publications.
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents
Molica, S; Seymour, JF; Polliack, A
(2021), Hematol. Oncol., 595-604
DOI: 10.1002/hon.2929
Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion
Tam, CS; Robak, T; Ghia, P; Kahl, BS; Walker, P; Janowski, W; Simpson, D; Shadman, M; Ganly, PS; Laurenti, L; Opat, S; Tani, M; Ciepluch, H; Verner, E; Simkovi, M; Osterborg, A; Trneny, M; Tedeschi, A; Paik, JC; Kuwahara, SB; Feng, SB; Ramakrishnan, V; Cohen, A; Huang, J; Hillmen, P; Brown, JR
(2021), Haematologica, 2354-2363
Myeloma natural killer cells are exhausted and have impaired regulation of activation
D'Souza, C; Keam, SP; Yeang, HXA; Neeson, M; Richardson, K; Hsu, AK; Canfield, R; Bezman, N; Robbins, M; Quach, H; Ritchie, DS; Harrison, SJ; Trapani, JA; Prince, HM; Beavis, PA; Darcy, PK; Neeson, PJ
(2021), Haematologica, 2522-2526
Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
Brodsky, RA; de Latour, RP; Rottinghaus, ST; Roth, A; Risitano, AM; Weitz, IC; Hillmen, P; Maciejewski, JP; Szer, J; Lee, JW; Kulasekararaj, AG; Volles, L; Damokosh, AI; Ortiz, S; Shafner, L; Liu, P; Hillc, A; Schrezenmeier, H
(2021), Haematologica, 230-237
Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing
Tian, LY; Jabbari, JS; Thijssen, R; Gouil, Q; Amarasinghe, SL; Voogd, O; Kariyawasam, H; Du, MRM; Schuster, J; Wang, CQ; Su, SA; Dong, XY; Law, CW; Lucattini, A; Prawer, YDJ; Collar-Fernandez, C; Chung, JD; Naim, T; Chan, A; Ly, CH; Lynch, GS; Ryall, JG; Anttila, CJA; Peng, HK; Anderson, MA; Flensburg, C; Majewski, I; Roberts, AW; Huang, DCS; Clark, MB; Ritchie, ME
(2021), Genome Biol.
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma
Dreyling, M; Tam, CS; Wang, M; Smith, SD; Ladetto, M; Huang, HQ; Novotny, W; Co, M; Romano, A; Holmgren, E; Huang, JE; Le Gouill, S
(2021), Future Oncol., 255-262
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Nooka, AK; Weisel, K; van de Donk, NWCJ; Routledge, D; Otero, PR; Song, KV; Quach, H; Callander, N; Minnema, MC; Trudel, S; Jackson, NA; Ahlers, CM; Im, E; Cheng, S; Smith, L; Hareth, N; Ferron-Brady, G; Brouch, M; de Oca, RM; Paul, S; Holkova, B; Gupta, I; Kremer, BE; Richardson, P
(2021), Future Oncol., 1987-2003
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
D'Souza, C; Prince, HM; Neeson, PJ
(2021), Front. Immunol.
Paving the way to precision medicine in multiple myeloma
Inam, S; Ross, JA; Touzeau, C; Moreau, P; Kumar, SK; Harrison, SJ
(2021), Expert Rev. Hematol., 323-327
Hematological manifestations and complications of Gaucher disease
Revel-Vilk, S; Szer, J; Zimran, A
(2021), Expert Rev. Hematol., 347-354
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib
Tam, CS; Ou, YC; Trotman, J; Opat, S
(2021), Expert Rev. Clin. Pharmacol., 1329-1344
Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients - the role of therapeutic drug monitoring
Ho, SA; Slavin, M; Roberts, JA; Yong, M
(2021), Expert Rev. Anti-Infect. Ther., 707-718
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction
Boyle, S; Wellard, C; Moore, EM; Blacklock, H; Harrison, SJ; Ho, PJ; Hocking, J; McQuilten, ZK; Quach, H; Spearing, R; Wood, EM; Spencer, A; Mollee, P
(2021), Eur. J. Haematol., 497-499
DOI: 10.1111/ejh.13677
Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15
MacManus, MP; Roos, D; O'Brien, P; Capp, A; Wirth, A; Tsang, R; Bressel, M; Lade, S; Seymour, JF
(2021), Eur. J. Cancer, 129-138
Transient, flexible gene editing in zebrafish neutrophils and macrophages for determination of cell-autonomous functions
Isiaku, AI; Zhang, ZB; Pazhakh, V; Manley, HR; Thompson, ER; Fox, LC; Yerneni, S; Blombery, P; Lieschke, GJ
(2021), Dis. Model. Mech.
DOI: 10.1242/dmm.047431
Evaluation of the Impact of Magnetic Resonance Imaging with Susceptibility-weighted Imaging for Screening and Surveillance of Radiation-induced Cavernomas in Long-term Survivors of Malignancy
Campbell, BA; Lasocki, A; Oon, SF; Bressel, M; Goroncy, N; Dwyer, M; Wiltshire, K; Seymour, JF; Mason, K; Tange, D; Xu, M; Wheeler, G
(2021), Clin. Oncol., E425-E432
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)
Bergin, K; Wellard, C; Moore, E; McQuilten, Z; Blacklock, H; Harrison, SJ; Ho, PJ; King, T; Quach, H; Mollee, P; Walker, P; Wood, E; Spencer, A
(2021), Clin. Lymphoma Myeloma Leuk., E510-E520
Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies
Lim, C; Sinha, P; Harrison, SJ; Quach, H; Slavin, MA; Teh, BW
(2021), Clin. Lymphoma Myeloma Leuk., 444
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis
Punnoose, E; Peale, FV; Szafer-Glusman, E; Lei, GY; Bourgon, R; Do, AD; Kim, E; Zhang, LP; Farinha, P; Gascoyne, RD; Munoz, FJ; Martelli, M; Mottok, A; Salles, GA; Sehn, LH; Seymour, JF; Trneny, M; Oestergaard, MZ; Mundt, KE; Vitolo, U
(2021), Clin. Lymphoma Myeloma Leuk., 267
Advances in Frontline Management of Peripheral T-cell Lymphoma
Abeyakoon, C; van der Weyden, C; Harrop, S; Khot, A; Dickinson, M; Yannakou, CK; Prince, HM
(2021), Clin. Lymphoma Myeloma Leuk., 368-378
Re-examining ferritin-bound iron: current and developing clinical tools
Grant, ES; Clucas, DB; McColl, G; Hall, LT; Simpson, DA
(2021), Clin. Chem. Lab. Med., 459-471
Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Davids, MS; Roberts, AW; Kenkre, VP; Wierda, WG; Kumar, A; Kipps, TJ; Boyer, M; Salem, AH; Pesko, JC; Arzt, JA; Mantas, M; Kim, SY; Seymour, JF
(2021), Clin. Cancer Res., 4690-4695
Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma
Doerflinger, M; Garnham, AL; Freytag, S; Harrison, SJ; Prince, HM; Quach, H; Slavin, MA; Pellegrini, M; Teh, BW
(2021), Clin. Transl. Immunol.
DOI: 10.1002/cti2.1235
Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy
Shanavas, M; Law, SC; Hertzberg, M; Hicks, RJ; Seymour, JF; Li, ZX; de Long, LM; Nath, K; Sabdia, MB; Gunawardana, J; Gandhi, MK; Keane, C
(2021), Clin. Transl. Immunol.
DOI: 10.1002/cti2.1351
Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects
Beaumont, S; Harrison, S; Er, J
(2021), Cancers
Venetoclax and navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Pullarkat, VA; Lacayo, NJ; Jabbour, E; Rubnitz, JE; Bajel, A; Laetsch, TW; Leonard, J; Colace, SI; Khaw, SL; Fleming, SA; Mattison, RJ; Norris, R; Opferman, JT; Roberts, KG; Zhao, YQ; Qu, CX; Badawi, M; Schmidt, M; Tong, B; Pesko, JC; Sun, Y; Ross, JA; Vishwamitra, D; Rosenwinkel, L; Kim, SY; Jacobson, A; Mullighan, CG; Alexander, TB; Stock, W
(2021), Cancer Discov., 1440-1453
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
Harrison, SJ; Perrot, A; Alegre, A; Simpson, D; Wang, MC; Spencer, A; Delimpasi, S; Hulin, C; Sunami, K; Facon, T; Vlummens, P; Yong, K; Campana, F; Inchauspe, M; Mace, S; Risse, ML; Velde, H; Richardson, P
(2021), Br. J. Haematol., 120-131
DOI: 10.1111/bjh.17499
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target
Gould, C; Lickiss, J; Kankanige, Y; Yemeni, S; Lade, S; Gandhi, MK; Chin, C; Yannakou, CK; Villa, D; Slack, GW; Markham, JF; Tam, CS; Nelson, N; Seymour, JF; Dickinson, M; Neeson, PJ; Westerman, D; Blombery, P
(2021), Br. J. Haematol., 113-118
DOI: 10.1111/bjh.17789
T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection
Kuzich, JA; Kankanige, Y; Guinto, J; Ryland, G; McBean, M; Wong, E; Koldej, R; Collins, J; Westerman, D; Ritchie, D; Blombery, P
(2021), Bone Marrow Transplant., 2582-2590
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)
Bergin, K; Wellard, C; Augustson, B; Cooke, R; Blacklock, H; Harrison, SJ; Ho, J; King, T; Quach, H; Mollee, P; Walker, P; Moore, E; McQuilten, Z; Wood, E; Spencer, A
(2021), Bone Marrow Transplant., 2533-2543